Agios Pharmaceuticals (AGIO) : Traders are bullish on Agios Pharmaceuticals (AGIO) as it has outperformed the S&P 500 by a wide margin of 19.26% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.84%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8.42% in the last 1 week, and is up 16.84% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 14.05% and the 50-Day Moving Average is 11.46%.The 200 Day SMA reached 0.45% Agios Pharmaceuticals, Inc. has dropped 1.81% during the last 3-month period . Year-to-Date the stock performance stands at -28.19%.
Agios Pharmaceuticals (AGIO) : The highest short term price target forecast on Agios Pharmaceuticals (AGIO) is $90 and the lowest target price is $49. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $65.75 with a standard deviation of $17.97.
For the current week, the company shares have a recommendation consensus of Buy. Agios Pharmaceuticals (NASDAQ:AGIO): The stock opened at $45.19 and touched an intraday high of $46.8 on Friday. During the day, the stock corrected to an intraday low of $45, however, the bulls stepped in and pushed the price higher to close in the green at $46.62 with a gain of 1.59% for the day. The total traded volume for the day was 1,187,937. The stock had closed at $46.62 in the previous trading session.
Agios Pharmaceuticals, Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221, AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.